# Alkermes (ALKS) — Earnings

ALKS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/alks/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.00 |
| EPS estimate | −$0.02 |
| EPS surprise | +100.00% |
| Revenue surprise | +8.45% |
| Revenue | $496.0M |
| Revenue estimate | $457.4M |
| Reported | Jul 28, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1520262/000119312526319022/alks-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/bae76944-3952-80db-9e0b-f4e2eda45d43.html) |

Alkermes reported Q2 2026 results on July 28, 2026. Earnings per share were $0.00, against an expected loss of $0.02, a 100% surprise by the source's measure. Revenue was $496.0 million, 8.45% above the $457.4 million consensus. Compared with Q2 2025, revenue rose about 27% from $390.7 million, while EPS fell from $0.67 to break-even.

The 2026 results follow a loss of $0.40 per share in Q1 2026, the only loss in the table. Annual EPS climbed from $0.32 in 2022 to $1.33 in 2023 and $2.90 in 2024, then eased to $1.91 in 2025. The quarterly high was $1.05 in Q4 2024. Revenue has been uneven: Q2 2023 stands out at $617.4 million, the highest in the table, while Q2 2026 is the second highest and up about 26% from Q1. Earnings surprises have been large in both directions. Alkermes beat the EPS estimate in 14 of the last 20 quarters, with misses as wide as 50.83% in Q4 2023.

Alkermes reported Q3 between October 24 and November 2 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether earnings return to profit.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 28, 2026 | −$0.02 | $0.00 | 100.00% | $457.4M | $496.0M |
| Q1 2026 | May 5, 2026 | −$0.54 | −$0.40 | 26.01% | $363.3M | $392.9M |
| Q4 2025 | Feb 25, 2026 | $0.41 | $0.29 | -29.30% | $378.9M | $384.5M |
| Q3 2025 | Oct 28, 2025 | $0.37 | $0.68 | 85.55% | $356.9M | $394.2M |
| Q2 2025 | Jul 29, 2025 | $0.38 | $0.67 | 75.87% | $341.4M | $390.7M |
| Q1 2025 | May 1, 2025 | $0.25 | $0.27 | 4.20% | $302.9M | $306.5M |
| Q4 2024 | Feb 12, 2025 | $0.77 | $1.05 | 36.15% | $379.4M | $430.0M |
| Q3 2024 | Oct 24, 2024 | $0.72 | $0.72 | -0.07% | $380.9M | $378.1M |
| Q2 2024 | Jul 24, 2024 | $0.70 | $0.70 | -0.57% | $393.3M | $399.1M |
| Q1 2024 | May 1, 2024 | $0.58 | $0.43 | -26.21% | $360.3M | $350.4M |
| Q4 2023 | Feb 15, 2024 | $0.45 | $0.22 | -50.83% | $362.2M | $377.5M |
| Q3 2023 | Oct 25, 2023 | $0.40 | $0.59 | 50.23% | $362.3M | $380.9M |
| Q2 2023 | Jul 26, 2023 | $0.37 | $0.51 | 39.24% | $458.1M | $617.4M |
| Q1 2023 | Apr 26, 2023 | $0.00 | $0.01 | 106.67% | $283.4M | $287.6M |
| Q4 2022 | Feb 16, 2023 | $0.04 | $0.13 | 210.50% | $289.8M | $304.7M |
| Q3 2022 | Nov 2, 2022 | $0.03 | $0.02 | -32.85% | $271.4M | $252.4M |
| Q2 2022 | Jul 27, 2022 | $0.01 | $0.06 | 745.45% | $269.0M | $276.2M |
| Q1 2022 | Apr 27, 2022 | $0.02 | $0.11 | 381.03% | $256.0M | $278.5M |
| Q4 2021 | Feb 16, 2022 | $0.07 | $0.21 | 187.75% | $306.5M | $324.5M |
| Q3 2021 | Oct 27, 2021 | $0.06 | $0.13 | 123.54% | $301.4M | $294.1M |

## Frequently Asked Questions

### When did Alkermes (ALKS) last report earnings?

Alkermes last reported on Jul 28, 2026, covering fiscal Q2 2026.

### Did ALKS beat earnings estimates?

Yes. Alkermes reported EPS of $0.00 for Q2 2026 against a −$0.02 estimate — a 100.00% beat.

### How much revenue did ALKS report last quarter?

Alkermes reported $496.0M in revenue for Q2 2026, against a consensus estimate of $457.4M.

## Similar Stocks

- [MEDP](https://www.lighthorse.io/tickers/medp) — Medpace Holdings, Inc. - Common Stock
- [AMN](https://www.lighthorse.io/tickers/amn) — AMN Healthcare Services Inc
- [OMCL](https://www.lighthorse.io/tickers/omcl) — Omnicell, Inc. - Common Stock
- [ABEO](https://www.lighthorse.io/tickers/abeo) — Abeona Therapeutics Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).